# Clinical trials recruiting in Peru: 117 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 117 trials recruiting or not yet recruiting with a site in Peru, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Peru: 117 rows for $5.85, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/peru

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 117
- Recruiting or not yet: 117
- Read on: November 19, 2026

## Trials

The 25 newest of 117, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 14, 2026 | NCT07818824 | A Clinical Study of the HCMV-TB Vaccine Candidate VIR-1778 in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | Tuberculosis | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818824) |
| August 10, 2026 | NCT07753993 | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease | 7,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753993) |
| June 25, 2026 | NCT07667738 | Evaluating the Effectiveness of the Common Elements Treatment Approach (CETA) in Peru: Mechanisms of Individual and Intergenerational Change | University of Notre Dame | Phase 2 | Recruiting | Violence, Parenting, Poverty, Depression, Mental Health, Posttraumatic Stress, Economic Factors, Child Psychology | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667738) |
| June 22, 2026 | NCT07658976 | Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy | HIV Prevention Trials Network | Phase 3 | Not yet recruiting | HIV Infection, Sexually Transmitted Infection | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658976) |
| June 18, 2026 | NCT07656012 | Re-evaluating the Duration in Children of TB Treatment | University of Wisconsin, Madison | Phase 2 | Not yet recruiting | Tuberculosis | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656012) |
| June 11, 2026 | NCT07643597 | Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients | Hospital Las Higueras | Observational | Recruiting | Acute Kidney Injury, Fluid Overload, Fluid Overload in Dialysis Patients, Critical Illness, Renal Replacement Therapy... | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643597) |
| June 5, 2026 | NCT07630714 | A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to \< 18 Years... | AstraZeneca | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630714) |
| June 3, 2026 | NCT07624305 | A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) | AstraZeneca | Phase 3 | Recruiting | Renal Insufficiency, Chronic | 2,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624305) |
| May 28, 2026 | NCT07612332 | Non-Immersive Virtual Reality for Gait and Balance Training in Children With Cerebral Palsy | Universidad Nacional de San Agustin de Arequipa | Not applicable | Not yet recruiting | Cerebral Palsy (CP) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612332) |
| May 19, 2026 | NCT07595042 | A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | Tuberculosis | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595042) |
| May 6, 2026 | NCT07569029 | A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Recruiting | HIV | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569029) |
| April 21, 2026 | NCT07543458 | Therapeutics for Moderate and Severe Dengue | Oxford University Clinical Research Unit, Vietnam | Phase 3 | Not yet recruiting | Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA... | 8,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543458) |
| March 2, 2026 | NCT07441408 | Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Pulmonary Fibrosis | 2,380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441408) |
| February 24, 2026 | NCT07430592 | This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Malaria, Malaria Vivax, Radical Cure | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430592) |
| February 5, 2026 | NCT07390955 | A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Recruiting | HIV | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390955) |
| January 23, 2026 | NCT07363590 | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363590) |
| January 23, 2026 | NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung... | Bristol-Myers Squibb | Phase 3 | Recruiting | Non-Small Cell Lung Cancer (NSCLC) | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07361510) |
| January 6, 2026 | NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Neoplasms, Ovarian Cancer | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318558) |
| December 16, 2025 | NCT07284459 | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Contineum Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284459) |
| December 11, 2025 | NCT07276724 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | Generate Biomedicines | Phase 3 | Recruiting | Severe Asthma | 786 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276724) |
| December 3, 2025 | NCT07262320 | Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America | University of Alabama at Birmingham | Observational | Recruiting | Dialysis, Critically Ill Acute Kidney Injury, Renal Replacement Therapy for Acute Kidney Injury in ICU, Acute Kidney... | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262320) |
| October 28, 2025 | NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated... | mAbxience Research S.L. | Phase 3 | Recruiting | Advanced (Unresectable or Metastatic) Melanoma | 632 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221734) |
| October 7, 2025 | NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209761) |
| September 26, 2025 | NCT07193771 | Altitude and Outcomes in Pediatric ARDS: A Multicenter Study | Latin American Pediatric Collaborative Network | Observational | Recruiting | Respiratory Distress Syndrome, Pediatric, Altitude Hypoxia, High Altitude Effects | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193771) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| IPOR Instituto Peruano de Oncología & Radioterapia | Lima | 14 |
| INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS | Lima | 7 |
| Hospital Nacional Edgardo Rebagliati Martins | Lima | 5 |
| Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) | Concepción | 4 |
| IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación | Lima | 4 |
| Hospital Cayetano Heredia | Lima | 4 |
| Instituto Nacional de Enfermedades Neoplásicas | Lima | 3 |
| Hospital Nacional Adolfo Guevara Velasco | Cusco | 3 |
| Oncosalud-Clinical Research | Lima | 3 |
| INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology | Lima | 3 |
| Instituto Nacional de Enfermedades Neoplasicas | Lima | 3 |
| Hospital Militar Central Luis Arias Schereiber | Jesus Maria | 3 |
| Instituto Neuro Cardiovascular de las Americas | Lima | 3 |
| Hospital Militar Central Coronel Luis Arias Schereiber | Lima | 2 |
| Hospital Nacional Guillermo Almenara Irigoyen | La Victoria, Lima | 2 |
| Hospital Nacional Arzobispo Loayza | Lima Cercado | 2 |
| Hospital Nacional Dos De Mayo | Lima | 2 |
| Unidad de Investigacion Oncologia Clínica Piura | Castilla | 2 |
| Hospital Guillermo Almenara Irigoyen | Lima | 2 |
| Universidad Peruana Cayetano Heredia | Piura | 2 |
| Hospital Cayetano Heredia-Oncology | Lima | 2 |
| Clinica Vallesur - AUNA | Arequipa | 2 |
| Hospital de Emergencias Pediatricas | Lima | 1 |
| Centro de Investigación del Hospital de Emergencias de Villa el Salvador | Villa El Salvador | 1 |
| Hospital Sergio E. Bernales | Lima | 1 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 19 |
| Phase 2/3 | 5 |
| Phase 3 | 61 |
| Not applicable | 9 |
| Observational | 16 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 12 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 7 |
| Neoplasms | 5 |
| Breast Neoplasms | 5 |
| Tuberculosis | 5 |
| Lupus Erythematosus, Systemic | 4 |
| Tuberculosis, Multidrug-Resistant | 3 |
| Prostatic Neoplasms | 3 |
| HIV Infections | 3 |
| Pulmonary Disease, Chronic Obstructive | 3 |
| Heart Failure | 3 |
| Lung Neoplasms | 3 |
| Renal Insufficiency, Chronic | 3 |
| Triple Negative Breast Neoplasms | 2 |
| Respiratory Distress Syndrome | 2 |
| Asthma | 2 |
| Tuberculosis, Pulmonary | 2 |
| Malaria | 2 |
| Malaria, Vivax | 2 |
| Depression | 2 |
| Lung Diseases, Interstitial | 2 |
| COVID-19 | 2 |
| Acute Kidney Injury | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lung Diseases | 2 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 27 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 21 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 8 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 3 |
| [Karuna Therapeutics, Inc., a Bristol Myers Squibb company](https://specstream.ai/data/clinical-trials/company/karuna-therapeutics-inc-a-bristol-myers-squibb-company) | 2 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| [Genzyme, a Sanofi Company](https://specstream.ai/data/clinical-trials/company/genzyme-a-sanofi-company) | 2 |
| Yale University | 2 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 2 |
| University of California, San Francisco | 2 |
| Swiss Tropical & Public Health Institute | 2 |
| Latin American Pediatric Collaborative Network | 1 |
| [Otsuka Pharmaceutical Development & Commercialization, Inc.](https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-development-and-commercialization-inc) | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| University of Wisconsin, Madison | 1 |
| Immune Oncology Research Institute | 1 |
| The George Institute | 1 |
| Boston Medical Center | 1 |
| [United Therapeutics](https://specstream.ai/data/clinical-trials/company/united-therapeutics) | 1 |
| Latin American Cooperative Oncology Group | 1 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 1 |
| University of Alabama at Birmingham | 1 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 1 |
| Grupo Espanol de Investigacion en Sarcomas | 1 |
| Johns Hopkins University | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ski resorts in the United States](https://specstream.ai/data/businesses/ski-resorts/united-states)
- [Sand and gravel suppliers in the United States](https://specstream.ai/data/businesses/sand-and-gravel-suppliers/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [Property management companies in the United States](https://specstream.ai/data/businesses/property-management-companies/united-states)
- [Polish restaurants in the United States](https://specstream.ai/data/businesses/polish-restaurants/united-states)
- [Pediatric pulmonology practices in the United States](https://specstream.ai/data/businesses/pediatric-pulmonology-practices/united-states)
